相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic high prolactin levels impact on gene expression at discrete hypothalamic nuclei involved in food intake
Felicitas Lopez-Vicchi et al.
FASEB JOURNAL (2020)
Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
Sarah Byberg et al.
ENDOCRINE CONNECTIONS (2019)
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas
Verena Schwetz et al.
METABOLIC BRAIN DISEASE (2017)
Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity — United States, 2005–2014
C. Brooke Steele et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)
Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Bozidar Peric et al.
ENDOCRINE RESEARCH (2016)
BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants
Dagfinn Aune et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants
Dagfinn Aune et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
Etienne Delgrange et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
Nazir A. Pala et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma
Tuncay Delibasi et al.
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION (2015)
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels
Alessandro Ciresi et al.
CLINICAL ENDOCRINOLOGY (2013)
Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia
Aysegul Atmaca et al.
ENDOCRINE (2013)
BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists
Cintia M. dos Santos Silva et al.
OBESITY (2011)
Body fat in nonobese women with prolactinoma treated with dopamine agonists
Erika C. O. Naliato et al.
CLINICAL ENDOCRINOLOGY (2007)
Advances in the treatment of prolactinomas
Mary P. Gillam et al.
ENDOCRINE REVIEWS (2006)
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia
J Korner et al.
OBESITY RESEARCH (2003)
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine
M Doknic et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Body weight gain after administration of antipsychotic drugs:: Correlation with leptin, insulin and reproductive hormones
T Baptista et al.
PHARMACOPSYCHIATRY (2000)
分享论文
